Is Regeneron a Multimillionaire-Maker Stock?

What: Regeneron Pharmaceuticals is a biotechnology company with a market capitalization of over $**150 billion**.
Why: The company's success can be attributed to its innovative pipeline of treatments for various diseases, including cancer, eye disorders, and infectious diseases.
Signal: Regeneron's stock price has consistently outperformed the market, with a compound annual growth rate of over **20%**.
Target: Investors are looking for the company to continue its growth trajectory, driven by the potential of its pipeline and increasing demand for its existing treatments.
Risk: Regeneron's stock price is highly volatile, and investors face significant risk if the company fails to meet expectations or faces regulatory setbacks.